Hatono et al.‘s study shed light on this phenomenon by revealing that equol exhibits dual actions on tumor growth in estrogen receptor-positive breast cancer cell lines: promoting cell growth at low concentrations while exerting anti-tumor effects at high concentrations [88]. Here, ESR1 is linked to breast cancer.